We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+15.1%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$126M
AUM Growth
-$105M
Cap. Flow
-$130M
Cap. Flow %
-103.25%
Top 10 Hldgs %
92.32%
Holding
24
New
8
Increased
4
Reduced
7
Closed
4

Top Buys

1
RVNC
Revance Therapeutics, Inc.
RVNC
+$11.7M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$4.9M
3
SCPH
scPharmaceuticals
SCPH
+$2.5M
4
TELA icon
TELA Bio
TELA
+$2.44M
5
NKTR icon
Nektar Therapeutics
NKTR
+$2.43M

Top Sells

1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$36.8M
2
EOLS icon
Evolus
EOLS
+$34.6M
3
QDEL icon
QuidelOrtho
QDEL
+$33.2M
4
ADMA icon
ADMA Biologics
ADMA
+$31.7M
5
XERS icon
Xeris Biopharma Holdings
XERS
+$13.8M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EOLS icon
1
Evolus
EOLS
$377M
$37.4M 29.7%
2,674,356
-2,658,648
-50% -$34.6M
ADMA icon
2
ADMA Biologics
ADMA
$2.02B
$22.6M 17.94%
3,426,882
-5,795,735
-63% -$31.7M
ALIM
3
DELISTED
Alimera Sciences
ALIM
$15.8M 12.53%
4,051,072
+51,613
+1% +$196K
LKFT
4
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$12.7M 10.05%
393,634
+131,764
+50% +$4.9M
RVNC
5
DELISTED
Revance Therapeutics, Inc.
RVNC
$9.72M 7.71%
+1,976,342
New +$11.7M
XOMA
6
DELISTED
Xoma
XOMA
$6.1M 4.84%
253,770
+3,770
+2% +$84.5K
TELA icon
7
TELA Bio
TELA
$32.7M
$3.9M 3.1%
688,200
+370,418
+117% +$2.44M
NKTR icon
8
Nektar Therapeutics
NKTR
$2.31B
$3.25M 2.58%
+232,027
New +$2.43M
MIST icon
9
Milestone Pharmaceuticals
MIST
$148M
$2.62M 2.08%
+1,462,296
New +$2.37M
SCPH
10
DELISTED
scPharmaceuticals
SCPH
$2.24M 1.78%
+446,776
New +$2.5M
CALC icon
11
CalciMedica
CALC
$11.6M
$2.17M 1.72%
+522,602
New +$2.39M
ANIK icon
12
Anika Therapeutics
ANIK
$203M
$1.55M 1.23%
+60,949
New +$1.47M
RIGL icon
13
Rigel Pharmaceuticals
RIGL
$750M
$1.54M 1.22%
+104,024
New +$1.4M
AYTU icon
14
AYTU BioPharma
AYTU
$23.1M
$1.44M 1.14%
472,469
– –
XERS icon
15
Xeris Biopharma Holdings
XERS
$1.52B
$1.32M 1.05%
598,086
-5,338,914
-90% -$13.8M
XGN icon
16
Exagen
XGN
$106M
$612K 0.49%
384,600
-285,084
-43% -$553K
ACET icon
17
Adicet Bio
ACET
$75.9M
$333K 0.26%
+8,847
New +$366K
RZLT icon
18
Rezolute
RZLT
$444M
$310K 0.25%
121,479
-2,647,177
-96% -$3.77M
IOBT
19
DELISTED
IO Biotech
IOBT
$270K 0.21%
156,167
-1,509,870
-91% -$2.62M
SCYX icon
20
SCYNEXIS
SCYX
$42.4M
$141K 0.11%
11,955
-157,443
-93% -$2.22M
AMLX icon
21
Amylyx Pharmaceuticals
AMLX
$1.97B
– –
-2,500,000
Closed -$36.8M
AVIR icon
22
Atea Pharmaceuticals
AVIR
$390M
– –
-839,514
Closed -$2.56M
QDEL icon
23
QuidelOrtho
QDEL
$1.19B
– –
-450,000
Closed -$33.2M
ATYR
24
aTyr Pharma
ATYR
$50M
– –
-482,258
Closed -$680K

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Stonepine Capital Management held 24 positions worth $126M, down 45% from $231M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Stonepine Capital Management withdrew a net $130M in Q1 2024, closing 4 positions and reducing 7 holdings. Its most notable exit was Amylyx Pharmaceuticals, an estimated $36.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in Revance Therapeutics, Inc. worth $9.72M.

  • Stonepine Capital Management's largest Q1 2024 buy was Revance Therapeutics, Inc.: 1,976,342 shares worth $9.72M.
  • Stonepine Capital Management added most to Lakefront Biotherapeutics American Depositary Shares in Q1 2024, an estimated $4.9M increase.
  • Stonepine Capital Management's biggest Q1 2024 reduction was Evolus, cutting an estimated $34.6M.
  • Stonepine Capital Management fully exited Amylyx Pharmaceuticals in Q1 2024, selling an estimated $36.8M.
  • Stonepine Capital Management's ten largest holdings make up 92% of its $126M portfolio in Q1 2024.
  • Stonepine Capital Management opened 8 new positions and closed 4 in Q1 2024.
  • Stonepine Capital Management's portfolio value fell 45% quarter-over-quarter to $126M.

Based on Stonepine Capital Management's 13F filing for Q1 2024, filed 15 May 2024.